FEASIBILITY AND EFFICACY OF INTRAVENOUS FERRIC DERISOMALTOSE TO CORRECT PRE-OPERATIVE IRON-DEFICIENCY ANEMIA IN PATIENTS UNDERGOING GYNECOLOGIC ONCOLOGY SURGERY: A PILOT RANDOMIZED DOUBLE BLINDED PARALLEL GROUP PLACEBO-CONTROLLED STUDY

Registry ID

FORGE II

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

ALBERTA HEALTH SERVICES

Start date

2026-06-16

Last update

2022-06-01

Conditions

• ANEMIA
• IRON DEFICIENCY

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALN-CFB, AN INVESTIGATIONAL SIRNA THERAPEUTIC AGAINST COMPLEMENT FACTOR B, IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND PERSISTENT ANEMIA ON APPROVED C5-INHIBITOR THERAPY
• A PHASE 2, RANDOMIZED, OPEN-LABEL, STUDY OF MOMELOTINIB IN PARTICIPANTS WITH ANEMIA DUE TO LOW-RISK MYELODYSPLASTIC SYNDROME
• A PHASE III, RANDOMISED, OPEN-LABEL, BLINDED ENDPOINT, COMPARATIVE TRIAL OF FERRIC DERISOMALTOSE VERSUS NO INTRAVENOUS IRON IN IRON-DEFICIENT SUBJECTS WITH SYMPTOMATIC CHRONIC HEART FAILURE
• A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-R) VERY LOW, LOW, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS) IN ERYTHROPOIESISSTIMULATING AGENT (ESA)-NAIVE PARTICIPANTS WHO ARE NON-TRANSFUSION DEPENDENT (NTD): THE ¿ELEMENT-MDS¿ TRIAL
• POST-OPERATIVE INTRAVENOUS IRON TO TREAT IRON-DEFICIENCY ANEMIA IN PATIENTS UNDERGOING CARDIAC SURGERY: A PILOT, MULTICENTRE, PLACEBO-CONTROLLED RANDOMIZED TRIAL (POAM)
• INTRAVENOUS IRON ISOMALTOSIDE VERSUS IRON SUCROSE FOR TREATMENT OF IRON DEFICIENCY IN PREGNANCY: RANDOMIZED, COMPARATIVE TRIAL

View on source registry